SSSonia Shah

Sonia Shah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sonia Shah has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: “There’s no representation”: a qualitative study of attitudes and motivations towards genomic research participation among Australian South Asians

    by Vaishnavi Nathan, Heena Akbar, Aideen McInerney-Leo, Deborah Gilroy, Anjali Henders, Reema Naresh, Nahid Choudhury, Maleeha Waqar, Sonia Shah, Tatiane Yanes, et al.

  • Open Access

    From GWAS to drug: A framework for drug candidate prioritisation using a gene expression signature matching approach

    by Solal Chauquet, Jiayue-Clara Jiang, Lauren F. Barker, Zoe L. Hunter, Gagandeep Singh, Naomi R. Wray, Allan F. McRae, Sonia Shah

    Drug targets supported by human genetic evidence have significantly higher approval rates, making genome-wide association studies a valuable resource for drug candidate prioritisation. Transcriptome-wide association study signature-matching is an emerging in silico approach that integrates GWAS data with expression quantitative trait loci to generate a disease gene expression signature, which is then compared against drug perturbation databases such as the Connectivity Map. Despite recent adoption, there is no consensus on optimal methodology. Here, we systematically benchmark key parameters, including TWAS method, eQTL tissue model, similarity metric, gene set size, and CMap cell line, using LDL cholesterol, familial combined hyperlipidemia, and asthma as proof-of-concept traits. We demonstrate that while TWAS signature-matching can successfully prioritise known first-line treatments, performance is highly sensitive to parameter choice; for instance, the selection of the cell line used for drug signatures alone can dramatically alter drug prioritisation. Based on these findings, we propose a best-practice framework for robust, genetically-informed drug prioritisation using TWAS signature-matching.

  • Open Access

    Glycaemic variability underlies myocyte dysfunction and myocardial injury risk in diabetes

    by Yuanzhao Cao, Meredith A. Redd, Jennifer E. Outhwaite, Dalia Mizikovsky, Woo Jun Shim, Chen Fang, Courtney Vedelago, Clarissa Tan, Zhixuan Wu, Dara Daygon, et al.

    Heart disease is the leading cause of morbidity and mortality in individuals with diabetes, due largely to risks associated with ischaemic injuries such as myocardial infarction (MI). We use human population genetic data to demonstrate that classical cardiovascular disease risk biomarkers, including common measures of hyperglycaemia, do not fully account for the increased risk of post-MI mortality in patients with diabetes. This study therefore systematically evaluates glycaemic stress underpinning cardiovascular risk in diabetes. Here, we show using in vivo studies in adult male mice and in vitro models that glycaemic variability, rather than sustained hyperglycaemia alone, is a key risk factor for cardiomyocyte dysfunction and increased susceptibility to myocardial injury in diabetes. We further demonstrate that patient plasma assays can elucidate the predictive potential of glycaemic variability as a primary contributor to cardiomyocyte dysfunction and subclinical cardiac injury in diabetes. These findings provide preclinical models for mechanistic and drug discovery studies and inform strategies for managing cardiovascular outcomes in patients with diabetes.

  • Open Access

    Applying machine-learning and deep-learning to predict depression from brain MRI and identify depression-related brain biology

    by Jiayue-Clara Jiang, Camille Brianceau, Elise Delzant, Romain Colle, Hugo Bottemanne, Emmanuelle Corruble, Naomi R. Wray, Olivier Colliot, Sonia Shah, Baptiste Couvy-Duchesne

    The accuracy of grey-matter predictors of depression has remained limited. In this study, brain-based predictors of major depressive disorder (MDD) were trained using machine-learning (Best Linear Unbiased Predictors [BLUP]) and deep-learning (ResNet3D) techniques applied to high-dimensional (voxel-wise) grey-matter structure extracted from T1-weighted structural MRI. The training sample comprised 987 MDD cases and 3934 controls from the UK Biobank. Predictors were evaluated in an independent sub-cohort of 483 MDD cases and 1939 controls from the UK Biobank and replicated in a clinical cohort (DEP-ARREST CLIN) of 64 cases and 32 controls. In the UK Biobank, the BLUP predictor showed a significant association with MDD status (AUC = 0.57; OR = 1.28 [1.15-1.43]; p-value = 1.1×10 -5 ), which was confirmed in both males and females. By partitioning the BLUP predictor by brain regions of interest (ROI), we found nominal significance supporting the contribution of previously identified MDD-related ROIs (e.g. hippocampus and amygdala), though none passed multiple testing correction. The BLUP predictor overlapped partially with a polygenic score (PGS) of major depression (AUC = 0.65) but also captured a nominally significant signal that was not captured by the genetic score (combined AUC = 0.66, p-value = 0.024 when compared to PGS alone). No association passed multiple testing correction in the DEP-ARREST CLIN cohort, likely due to the small sample size. In contrast, the deep-learning predictor was not associated with MDD after multiple testing corrections. We estimated the morphometricity of MDD to be 0.061, implying limited potential of a brain-based predictor based on grey-matter structure (maximal AUC = 0.64). While the modest AUC values reiterate the challenge of developing brain-based MDD predictors for clinical applications, our predictors inform future research to explore brain-based relationships between MDD and comorbidities.


  • Open Access

    Cohort Profile: Investigating Antidepressant Response within Generation Scotland

    by Megan L Calnan, Amelia Edmonson-Stait, Hannah Milbourn, Esme Elsden, Anjali K. Henders, Emily L. Ball, Matthew H. Iveson, AMBER Research Team, Amber Lived Experience Advisory Panel, Generation Scotland Team, et al.

    Background: The Antidepressant Medications: Biology, Exposure & Response (AMBER) research programme was established to investigate the biological mechanisms underlying antidepressant action and variability in treatment response. Generation Scotland holds detailed genomic, clinical, and health information with recontacting consent, making this cohort ideal for investigating these aims. Methods: We deployed a questionnaire, developed with input from a Lived Experience panel, to the Generation Scotland cohort to gather data on their depressive symptoms, medication history, efficacy, and side effects to develop clinically meaningful phenotypes of antidepressant response. Invitations were sent to 15,117 Generation Scotland participants who were 18 years or older and consented to be recontacted. Between July and November 2025, 1,180 participants with a history of antidepressant treatment for depression completed the questionnaire. Results: The sample was predominantly female (78.1%), self-identified as White (98.6%), and older (median age 57 years) than the wider Generation Scotland cohort (median 49 years) and Scottish population (median 41.3 years). Participants reported heterogeneous depressive symptom profiles spanning mood, anxiety, cognitive, sleep, behavioural, and physical domains. One-third of participants (31.1%) had taken three or more different antidepressants. Selective serotonin reuptake inhibitors (SSRIs) were the most common class (89.1%). Using self-reported treatment duration, discontinuation patterns, and efficacy, we developed a stringent classification system to capture treatment response extremes, where 23.8% were classified as responders and 1.5% as non-responders, with the majority unclassified. Conclusions: Questionnaire data will be linked with electronic health records to validate antidepressant response classifications. Following validation, 25 responders and 25 non-responders will provide biological samples for DNA methylation profiling and generation of patient-derived cell lines. These models will be exposed to SSRIs to identify gene expression signatures and biological pathways distinguishing treatment response, integrating with genomic and clinical data across the AMBER project. These findings will provide a valuable resource for future antidepressant response research. Plain Language Summary: Depression is a common mental health condition affecting millions of people worldwide. Antidepressant medications are the primary medication treatment, but response is highly variable with only about one-third of individuals achieving full symptom remission after their first medication trial. We don’t fully understand why some people respond well while others don’t. To help answer this question, the Antidepressant Medications: Biology, Exposure & Response (AMBER) research programme was established. This study utilised the Generation Scotland cohort, a large health study in Scotland. Between July and November 2025, we invited 15,117 Generation Scotland participants to complete a detailed questionnaire about their experiences with antidepressant medications. A total of 1,180 participants answered detailed questions about their depression symptoms, which medications they tried, how long they were on a medication, how well the medications worked, and what side effects they experienced. We found that people’s experiences with depression and antidepressants varied considerably. About one-third had tried three or more different antidepressants. Using strict criteria based on treatment duration, effectiveness ratings, and medication changes, we identified 281 people (24%) who responded very well to SSRIs (the most common type of antidepressant) and 18 people (1.5%) who did not respond despite trying multiple SSRIs. A key limitation is that all information was self-reported, so we will validate findings by linking questionnaire responses with medical records. In the future, we will collect blood samples from some participants to study the biological differences between responders and non-responders. This research will help us better understand why antidepressants work for some people but not others, which could lead to more personalised treatment approaches for depression.

  • Open Access

    Springfield Healthy Hearts Data Framework Protocol: A co-designed, city-wide, multi-component initiative that coordinates, monitors and evaluates place-based heart health action. (Preprint)

    by Lauren Ball, Kirsten N Adlard, David Chua, Amy Kirkegaard, Genevieve N Healy, Sarah A McNaughton, Jason Ferris, Sonia Shah, George Thomas, Benjamin J Seligmann, et al.

    Background: Cardiovascular disease remains the leading global cause of mortality, driven by interrelated behavioral, biological, and psychosocial risk factors, despite the availability of effective prevention and treatment strategies. Persistent policy inertia, systemic fragmentation, and adverse social and commercial determinants have limited national responses. Addressing these gaps necessitates place-based, systems-oriented approaches that mobilize local assets, engage multisector stakeholders, and incorporate adaptive evaluation. The Springfield Healthy Hearts initiative exemplifies such an approach by positioning Greater Springfield as a “living laboratory” for coordinated cardiovascular health action through a comprehensive data framework, providing a replicable model for other communities. Objective: This protocol outlines the Springfield Healthy Hearts Data Framework, a multicomponent system for dynamically guiding, implementing, and evaluating coordinated action for heart health. Methods: The data framework was developed through a structured co-design process involving community members, expert researchers, health professionals, and representatives from local implementation partners. The framework comprises four integrated components: (1) Project evaluation , applying pragmatic frameworks to assess coordinated action projects; (2) Community evaluation , a repeated cross-sectional evaluation of Springfield residents, workers, and regular visitors to capture individual-level behavioral, biological, and psychosocial cardiovascular disease risk factors, as well as engagement with coordinated action projects; (3) City evaluation , ongoing monitoring of suburb- and city-level indicators across 4 domains (sociodemographic characteristics, built environment, food and commercial environment, and health services); and (4) Data synthesis , to utilize data across all levels to inform a continuous learning system. Project evaluations will use both quantitative and qualitative methods, including realist evaluation where appropriate. Community evaluation will be analyzed using descriptive statistics, mixed effects models, and subgroup analyses, with missing data addressed via multiple imputation. City-level data will be analyzed descriptively and dynamically to detect temporal trends and contextual changes. Results: Initial funding for the Springfield Healthy Hearts Data Framework was secured in June 2025. Co-design workshops were conducted between November 2025 and February 2026 (n=15 participants), informing the design and prioritization of framework components. Community evaluation data collection is scheduled to commence in September 2026 and conclude in August 2027. Data cleaning and preliminary analyses are anticipated in late 2027, with first results expected to be disseminated in early 2028. Conclusions: The Springfield Healthy Hearts Data Framework is a replicable model for other communities aiming to implement city-wide, coordinated approaches to heart health action. Findings will be disseminated through peer-reviewed publications, community reports, interactive dashboards, and policy briefs.

  • Open Access

    Springfield Healthy Hearts Data Framework Protocol: A co-designed, city-wide, multi-component initiative that coordinates, monitors and evaluates place-based heart health action. (Preprint)

    by Lauren Ball, Kirsten N Adlard, David Chua, Amy Kirkegaard, Genevieve N Healy, Sarah A McNaughton, Jason Ferris, Sonia Shah, George Thomas, Benjamin J Seligmann, et al.

    BACKGROUND Cardiovascular disease remains the leading global cause of mortality, driven by interrelated behavioral, biological, and psychosocial risk factors despite the availability of effective prevention and treatment strategies. Persistent policy inertia, systemic fragmentation, and adverse social and commercial determinants have limited national responses. Addressing these gaps necessitates place-based, systems-oriented approaches that mobilize local assets, engage multi-sector stakeholders, and incorporate adaptive evaluation. The Springfield Healthy Hearts initiative exemplifies such an approach by positioning Greater Springfield as a “living laboratory” for coordinated cardiovascular health action through a comprehensive data framework, providing a replicable model for other communities. OBJECTIVE This protocol outlines the Springfield Healthy Hearts Data Framework; a multi-component system for dynamically guiding, implementing and evaluating coordinated action for heart health. METHODS The Data Framework was developed through a structured co-design process involving community members, expert researchers, health professionals, and representatives from local implementation partners. The framework comprises four integrated components: (1) Project Evaluations, applying pragmatic frameworks to assess coordinated action projects; (2) Community Evaluation, a repeated cross-sectional evaluation of Springfield residents, workers and regular visitors to capture individual-level behavioural, biological and psychosocial CVD risk factors, as well as engagement with coordinated action projects; and (3) City Evaluation, ongoing monitoring of suburb- and city-level indicators across four domains: sociodemographic characteristics, built environment, food and commercial environment and health services. (4) Data Synthesis, to utilise data across all levels to inform a continuous learning system. Project evaluations will use both quantitative and qualitative methods, including realist evaluation where appropriate. Community evaluation will be analysed using descriptive statistics, mixed-effects models and subgroup analyses, with missing data addressed via multiple imputation. City-level data will be analysed descriptively and dynamically to detect temporal trends and contextual changes. RESULTS As of February 2026, we have held two Data Framework co-design workshops with 15 community members. Their input, priorities and needs have informed our framework’s components. CONCLUSIONS The Springfield Healthy Hearts Data Framework is a replicable model for other communities aiming to implement city-wide, coordinated approaches to heart health action. Findings will be disseminated through peer-reviewed publications, community reports, interactive dashboards, and policy briefs.

  • Open Access

    Utility of polygenic risk scores in diagnostic genetic testing for dilated cardiomyopathy

    by Utpala Nanda Chowdhury, Eleni Giannoulatou, Diane Fatkin, John J. Atherton, Nathan J Palpant, Baptiste Couvy-Duchesne, Sonia Shah

    Dilated cardiomyopathy (DCM) is a major driver of heart failure and transplantation. Despite its strong genetic basis, clinical genetic testing identifies pathogenic/likely pathogenic (P/LP) variants in only about one-third of cases. Genome-wide association studies (GWAS) indicate that common variants also contribute to genetic risk, but utility of polygenic risk score (PRS) for diagnostic testing is unclear. We derived a DCM PRS from a large GWAS and applied it to 113 Australian Genomics Health Alliance (AGHA) participants of genetically determined European ancestry with clinically diagnosed DCM, with most having a family history of disease. Genetic testing identified a P/LP variant in 34% of patients. Using 450,280 UK Biobank participants of European ancestry as a reference, we selected the best performing PRS (SBayesRC; odds ratio per SD increase in PRS = 1.72, 95% CI 1.58–1.88). We compared the PRS of individuals with a P/LP variant in the TTN gene ( TTN_ G+) or other genes (non TTN_ G+), and in those without any P/LP or variants of unknown significance identified (G-). Relative to the UK Biobank reference, median PRS values were significantly higher in G- and TTN _G+ groups. Twenty-six percent of G- and 25% of TTN _G+ cases were in the top decile, versus 11% of non TTN _G+ cases. Notably, TTN _G+ cases were absent from the lowest four deciles. These findings support a substantial polygenic contribution in DCM patients without identifiable monogenic variants as well as in TTN -related DCM. Incorporating PRS alongside routine genetic testing could increase diagnostic yield and inform risk management for patients and families.

  • Open Access

    Dienogest interrupts the chemokine signalling axis in endometriotic lesions with resistant signatures providing novel opportunities for personalised treatment.

    by Brett McKinnon, Lea Duempelmann, Jitka Skrabalova, Sugarniya Subramaniam, Lea Taylor, Sharat Atluri, Solal Chauquet, Grant Montgomery, Keisuke Tanaka, Susanne Ramm, et al.

    Progestins are important first line and adjuvant medications for endometriosis, yet their efficacy varies among patients. Dienogest (DNG), a 4th generation progestin, is one of the most prescribed and successful progestins, although a subset of patients remain refractory to treatment. A prospective method to match patients to DNG, or other treatments could significantly improve patient outcomes. We employed a multidisciplinary approach using archival patient samples, clinical data, single nuclei sequencing, in silico prediction and high-content organoid drug screening to investigate DNG's impact on endometriotic lesions, signatures of non-response, and treatment options for refractory patients. We found DNG represses the inflammatory phenotype of deeply infiltrating endometriotic lesions by disrupting the chemokine signalling axis. Refractory patients displayed altered epithelial and stromal cell composition, aberrant progesterone receptor co-repressor signalling and enhanced TGF-B mediated fibrosis. Computational drug predictions identified potential therapies for refractory cases, including glucocorticoid receptor agonists for stroma- and immune-rich lesions, and HSP90 or NF-κB inhibitors for epithelial-dominant lesions, the activity of which were validated in high content screening of patient derived organoids. Notably some progestins already approved for endometriosis management possess off-target glucocorticoid activity, providing immediate potential for personalized treatment selection.

  • Open Access

    Unsupervised Variant Clustering Identifies Genetic Subtypes of Disease

    by Dalia Mizikovsky, Naomi R. Wray, Sonia Shah, Nathan Palpant

    Current approaches to identify disease subtypes rely on prior knowledge or external phenotypic references that limit their generalisability across traits. This study presents an unsupervised, phenotype- free framework that analyses the genetic co-occurrence of variants across individuals to identify variant clusters underpinning disease heterogeneity. The approach is developed and validated using simulated combinations of real phenotypes then applied to dissect disease subtypes of type 2 diabetes and asthma. The approach captures clinically established mechanistic profiles in type 2 diabetes and asthma without requiring any reference phenotype data and enables identification of plasma proteins for novel subtype- specific biomarkers and drug targets. Lastly, we demonstrate that variants with conflicting effects on disease-relevant traits are resolved into distinct clusters, identifying subtypes with opposing phenotypic profiles that are lost by the aggregated genetic risk. Co-occurrence-based clustering provides a scalable strategy for understanding disease heterogeneity across diverse populations by identifying biologically meaningful subtype structure from genotype data alone.